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AnBACKGROUND In GALACTIC-HF (Global Approach to Lowering Adverse Cardiac outcomes Through Improving
Contractility in Heart Failure) (n ¼ 8,256), the cardiac myosin activator, omecamtiv mecarbil, significantly reduced the
primary composite endpoint (PCE) of time-to-first heart failure event or cardiovascular death in patients with heart
failure and reduced ejection fraction (EF) (#35%).
OBJECTIVES The purpose of this study was to evaluate the influence of baseline EF on the therapeutic effect of
omecamtiv mecarbil.
METHODS Outcomes in patients treated with omecamtiv mecarbil were compared with placebo according to EF.
RESULTS The risk of the PCE in the placebo group was nearly 1.8-fold greater in the lowest EF (#22%) compared with the
highest EF ($33%) quartile. Amongst the pre-specified subgroups, EF was the strongest modifier of the treatment effect of
omecamtiv mecarbil on the PCE (interaction as continuous variable, p¼ 0.004). Patients receiving omecamtiv mecarbil had a
progressively greater relative and absolute treatment effect as baseline EF decreased, with a 17% relative risk reduction for the
PCE in patients with baseline EF#22% (n¼ 2,246; hazard ratio: 0.83; 95% confidence interval: 0.73 to 0.95) compared with
patients with EF $33% (n ¼ 1,750; hazard ratio: 0.99; 95% confidence interval: 0.84 to 1.16; interaction as EF by quartiles,
p¼ 0.013). The absolute reduction in the PCE increased with decreasing EF (EF#22%; absolute risk reduction, 7.4 events per
100 patient-years; number needed to treat for 3 years ¼ 11.8), compared with no reduction in the highest EF quartile.
CONCLUSIONS Inheart failurepatientswith reducedEF,omecamtivmecarbil producedgreater therapeuticbenefit asbaseline
EF decreased. These findings are consistentwith the drug’smechanismof selectively improving systolic function and presents an
important opportunity to improve the outcomes in a group of patients at greatest risk. (Registrational Study With Omecamtiv
Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction [GALACTIC-HF]; NCT02929329)
(J Am Coll Cardiol 2021;78:97–108) Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2021.04.065
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98M any therapies have been devel-oped that improve cardiovascu-lar outcomes in patients with
heart failure with reduced ejection fraction
(HFrEF). However, none of the currently
available drugs directly improve the central
defect of HFrEF: reduced systolic function.
Moreover, severe impairment of systolic
function is often associated with lower blood
pressure and greater difficulty toleratingSEE PAGE 109target doses of guideline-directed medical therapies.
Myotropes (1) represent a new class of drugs that
improve myocardial function by directly augmenting
cardiac sarcomere function. The cardiac myosin acti-
vator, omecamtiv mecarbil (2,3), is the first of this
class, and it increases systolic function by selectively
facilitating the actin-myosin interaction, increasing
contractile force without altering the cardiomyocyte
calcium transient (4). In patients with chronic HFrEF
enrolled in COSMIC-HF (Chronic Oral Study of Myosin
Activation to Increase Contractility in Heart Failure),
omecamtiv mecarbil increased left ventricular sys-
tolic function, as reflected by increased systolic ejec-
tion time and ejection fraction (EF) and improved
myocardial strain, while decreasing left ventricular
systolic and diastolic volumes, natriuretic peptide
concentrations, and heart rate (5,6). The GALACTIC-
HF (Global Approach to Lowering Adverse Cardiac
outcomes Through Improving Contractility in
Heart Failure) trial was the first trial to demonstrate
a beneficial effect of selectively increasing cardiac
contractility on cardiovascular outcomes in patients
with HFrEF (7–9). Here, we examine the impact of
baseline EF, a pre-specified subgroup, as a modifier
of the effect of omecamtiv mecarbil on clinical
outcomes and safety in patients enrolled in
GALACTIC-HF (NCT02929329; EudraCT number
2016-002299-28).
METHODS
GALACTIC-HF STUDY DESIGN. The design, baseline
characteristics, and primary results of the trial have
been previously published (7–9). Briefly, GALACTIC-
HF was a phase 3, global, double-blind, placebo-enna, Austria; jUniversity of Utah, Salt Lake City, Utah, USA;
USA; lCardiology Department, Middlemore Hospital, Otahuhu, A
tama, Japan; nMontreal Heart Institute and Université de Mont
Wroclaw, Poland; pUniversity Hospital St. Ann and Medical Facu
ornia, USA; and the rCytokinetics, Inc., South San Francisco, Cali
s attest they are in compliance with human studies committe
and Food and Drug Administration guidelines, including patien
thor Center.
received April 12, 2021; revised manuscript received April 26, 20controlled randomized clinical trial that compared
omecamtiv mecarbil to placebo in 8,256 patients with
symptomatic (New York Heart Association [NYHA]
functional class II to IV) HFrEF and EF#35% as per the
patient’s most recent medical record within 12 months
prior to screening. The most recent qualifying EF was
to be at least 30 days after any of the following, if
applicable: 1) an event likely to decrease EF (eg,
myocardial infarction, sepsis); 2) an intervention likely
to increase EF (eg, cardiac resynchronization therapy,
coronary revascularization); or 3) the first ever pre-
sentation for heart failure. All participants were
required to have elevated natriuretic peptides (N-ter-
minal pro–B-type natriuretic peptide [NT-proBNP]
level $400 pg/ml [1,200 pg/ml for patients in atrial
fibrillation] or B-type natriuretic peptide [BNP] $125
pg/ml [375 pg/ml for patients in atrial fibrillation]) and
were on optimized background heart failure therapy.
Participants were currently hospitalized for heart
failure (inpatients) or within 1 year had either an ur-
gent visit to the emergency department for heart fail-
ure or a hospitalization for heart failure (outpatients).
Key exclusion criteria included current hemodynamic
or clinical instability requiring mechanical or intrave-
nous medication, systolic blood pressure <85 mm Hg,
estimated glomerular filtration rate <20 ml/
min/1.73m2, recent acute coronary syndrome events or
cardiovascular procedures (including planned pro-
cedures), and other conditions with reduced life
expectancy <2 years or that would adversely affect
participation in the trial. The study protocol was
approved by the relevant local ethics committees, and
all participants provided informed consent.STUDY OUTCOMES. The primary outcome was a
composite of the time-to-first heart failure event or
death due to cardiovascular causes. Secondary out-
comes included the time to cardiovascular death;
change in Kansas City Cardiomyopathy Questionnaire
Total Symptom Score (KCCQ-TSS) from baseline to
week 24 using a scale from 0 to 100, with a higher
score indicating fewer symptoms; time to first heart
failure hospitalization; and time to all-cause death.
Additional exploratory outcomes have beenkHenry Ford Heart and Vascular Institute, Detroit,
uckland, New Zealand; mSaitama Citizens Medical
réal, Montreal, Quebec, Canada; oWroclaw Medical
lty, Brno, Czech Republic; qAmgen, Inc., Thousand
fornia, USA.
es and animal welfare regulations of the authors’
t consent where appropriate. For more information,
21, accepted April 26, 2021.
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99published (9). All deaths, HF events, major cardiac
ischemic events (myocardial infarction/unstable
angina hospitalization and coronary revasculariza-
tion), and strokes were adjudicated by an indepen-
dent external Clinical Events Committee (Duke
Clinical Research Institute) using standardized defi-
nitions (10).
STATISTICAL ANALYSIS. The initial analysis plan
defined subgroups according to median baseline EF;
however, for the purposes of this paper, we further
evaluated baseline characteristics for patients by
quartiles of EF. Continuous variables were summa-
rized via means and SDs or medians and interquartile
ranges, as appropriate. Categorical variables are
summarized with counts and percentages. Tests of
trend across categories were conducted via linear
regression, Cuzick’s nonparametric trend test, and
chi-square tests of trend, respectively. Treatment ef-
fects on continuous outcomes were assessed via
linear regression models adjusted for the corre-
sponding baseline value of the parameter of interest.
Survival analyses were conducted using Poisson
regression models to estimate incidence rates, rate
differences, and rate ratios and Cox proportional
hazards models to estimate hazard ratios (HRs).
Treatment effect HRs were adjusted for estimated
glomerular filtration rate and stratified by region and
inpatient status as in the primary GALACTIC-HF
analysis. To allow for potentially nonlinear associa-
tions between EF and time-to-event outcomes,
restricted cubic splines were utilized in the Poisson
regression models with 3 knots. Treatment effect
modification was assessed via the introduction of
interaction terms between randomized treatment
assignment and the corresponding EF model cova-
riates (eg, linear, quartile, or cubic spline). All ana-
lyses were conducted using STATA version 16
(StataCorp, College Station, Texas). All p values <0.05
were considered statistically significant. Due to the
exploratory nature of these analyses, no adjustments
were made for multiple comparisons.
RESULTS
STUDY PATIENTS. All of the 8,232 participants had
reported EFs with over 97% measured by echocar-
diogram (Supplemental Table 1, Supplemental
Figures 1 and 2), and there were 4,456 patients with
an EF #28%, the median EF in the trial. Due to digit
preference for EF assessment, over 70% of the pa-
tients had an EF #30%. When assessed by quartiles
(Table 1, Supplemental Table 2), patients with lower
EFs were younger; more likely to be male and non-
White; less likely to be enrolled in Eastern Europeor Russia; and more likely to be enrolled in the United
States, Canada, Western Europe, South Africa, or
Australasia. Patients with lower EF were more likely
to have a nonischemic etiology of heart failure, NYHA
functional class III/IV, lower body mass index, lower
systolic blood pressure, higher heart rate, higher NT-
proBNP, and higher cardiac troponin I, and were less
likely to have coronary artery disease, hypertension,
type 2 diabetes mellitus, or atrial fibrillation/flutter.
Lower EF was associated with greater symptom
burden in patients enrolled as inpatients (lower
KCCQ-TSS), but there was no meaningful difference
in the outpatients. There was no difference in the
proportion of patients receiving triple therapy
([angiotensin-converting enzyme inhibitor, angio-
tensin receptor blocker, or angiotensin receptor
neprilysin inhibitor] þ mineralocorticoid receptor
antagonist þ beta-blocker) among the EF quartiles.
Patients with lower EFs had higher use of
angiotensin-receptor neprilysin inhibitor, ivabradine,
digitalis glycosides, cardiac resynchronization ther-
apy, and implantable cardioverter-defibrillators
compared with patients with higher EFs.
RELATIONSHIP BETWEEN EF AND CLINICAL OUTCOMES.
Within the group of patients with HFrEF enrolled in
the GALACTIC-HF trial, the incidence of clinical out-
comes increased with decreasing EF (Table 2). As
noted by the rates in the placebo group, the incidence
of the primary outcome of first heart failure event or
cardiovascular death in patients in the lowest EF
quartile (EF #22%; 35.6 per 100 patient-years) was
almost 80% greater than in the highest EF quartile
(EF $33%; 20 per 100 patient-years). The incidence of
first heart failure event was 90% greater (28.3 events
vs 14.9 events per 100 patient-years) and of cardio-
vascular death was 68% greater (14.1 deaths vs 8.4
deaths per 100 patient-years) in the lowest EF
compared to the highest EF quartile. Participants in
the placebo group had significant improvements in
the KCCQ-TSS at week 24 compared with baseline,
with greater improvements in those enrolled as in-
patients, but there was no modification of this effect
by EF quartile (Supplemental Table 3).
INFLUENCE OF EF ON THE TREATMENT EFFECT OF OME-
CAMTIV MECARBIL. Omecamtiv mecarbil significantly
decreased the primary endpoint of the time-to-first
heart failure event or cardiovascular death in the
overall trial population (HR: 0.92; 95% confidence
interval [CI]: 0.86-0.99; p ¼ 0.025) (8). The statistical
analysis plan pre-specified the assessment of the
primary endpoint in the EF subgroups above and
below the median value (#28%), and there was a
significant modification of the treatment effect of








(n ¼ 1,750) p Value
Demographics
Age, yrs 62.5  11.8 64.1  11.6 65.7  10.9 66.4  10.5 <0.001
Female 422 (18.8) 451 (20.4) 455 (22.5) 421 (24.1) <0.001
Race <0.001
Asian 171 (7.6) 224 (10.1) 179 (8.8) 136 (7.8)
Black or African American 243 (10.8) 156 (7.1) 95 (4.7) 68 (3.9)
Other* 200 (8.9) 162 (7.3) 118 (5.8) 83 (4.7)
White 1,632 (72.7) 1,668 (75.5) 1,634 (80.7) 1,463 (83.6)
Geographic region <0.001
Asia 152 (6.8) 214 (9.7) 174 (8.6) 130 (7.4)
Eastern Europe/Russia 476 (21.2) 617 (27.9) 783 (38.6) 805 (46.0)
Latin and South America 438 (19.5) 504 (22.8) 364 (18.0) 268 (15.3)
United States and Canada 581 (25.9) 341 (15.4) 259 (12.8) 205 (11.7)
Western Europe/South Africa/Australasia 599 (26.7) 534 (24.2) 446 (22.0) 342 (19.5)
Randomization setting: in-patient 592 (26.4) 552 (25.0) 487 (24.0) 453 (25.9) 0.50
Clinical characteristics
Medical conditions
Coronary artery disease 1,267 (56) 1,320 (60) 1,323 (65) 1,218 (70) <0.001
Stroke 214 (10) 194 (9) 250 (12) 161 (9) 0.80
Atrial fibrillation or flutter history 912 (41) 884 (40) 889 (44) 790 (45) <0.001
Atrial fibrillation or flutter at screening 547 (24.4) 561 (25.4) 609 (30.1) 528 (30.2) <0.001
Hypertension 1,431 (64) 1,483 (67) 1,503 (74) 1,367 (78) <0.001
Type 2 diabetes mellitus 869 (39) 880 (40) 817 (40) 743 (43) <0.001
Chronic obstructive pulmonary disease 352 (16) 360 (16) 332 (16) 301 (17) 0.21
Heart failure history
LVEF, % 20 (15, 20) 25 (25, 27) 30 (30, 31) 34 (33, 35) N/A
Time from last HF event, months (outpatients only) 2.9 (1.6, 5.8) 3.1 (1.6, 6.1) 3.3 (1.6, 6.5) 3.4 (1.5, 6.8) 0.039
Time from last HF hospitalization, months (outpatients only) 3.0 (1.6, 5.9) 3.2 (1.6, 6.2) 3.4 (1.7, 6.6) 3.6 (1.6, 6.9) 0.043
MAGGIC score 25 (21, 30) 24 (20, 28) 22 (17, 26) 21 (17, 25) <0.001
NYHA functional classification 0.016
II 1,160 (52) 1,164 (53) 1,085 (54) 959 (55)
III 1,007 (45) 968 (44) 889 (44) 752 (43)
IV 79 (4) 78 (4) 52 (3) 39 (2)
Ischemic heart failure etiology 1,033 (46) 1,153 (52) 1,141 (56) 1,088 (62) <0.001
KCCQ total symptom score 69 (48, 88) 70 (49, 88) 71 (50, 88) 69 (49, 85) 0.77
Outpatient 75 (56, 92) 75 (54, 92) 75 (56, 92) 73 (54, 90) 0.05
Inpatient 51 (29, 69) 53 (33, 73) 55 (35, 72) 54 (31, 74) 0.022
Vitals and laboratory parameters
Body mass index, kg/m2 27.9  6.3 28.2  6.2 28.9  6.0 29.1  6.1 <0.001
SBP, mm Hg 112  15 115  15 119  15 121  14 <0.001
Heart rate, beats/min 74  12 72  12 72  12 72  12 <0.001
NT-proBNP, pg/ml 2,524 (1,250, 5,296) 2,035 (1,057, 4,157) 1,866 (924, 3,655) 1615 (755, 3,245) <0.001
hsTnI (ng/l), median (Q3) 31 (58) 29 (55) 26 (48) 23 (43) <0.001
eGFR, ml/min/1.73 m2 59 (44, 74) 59 (44, 75) 59 (43, 74) 58 (45, 74) 0.72
Continued on the next page
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100omecamtiv mecarbil by EF (interaction p ¼ 0.004).
This significant interaction persisted (p ¼ 0.009) after
further adjustment for all potential effect modifiers
reported previously as pre-specified subgroups (8). In
patients with EF #28%, there was a 16% reduction in
the time-to-first heart failure event or cardiovascular
death (HR: 0.84; 95% CI: 0.77-0.92; p ¼ 0.0003)
compared with no difference in patients with EF
>28% (HR: 1.04; 95% CI: 0.94-1.16; p ¼ 0.45). Analysisby quartiles of EF of the modifying effect on the pri-
mary composite endpoint (interaction p ¼ 0.013)
(Table 2, Supplemental Figure 3) by treatment with
omecamtiv mecarbil demonstrated a 15% (HR: 0.85;
95% CI: 0.74-0.97; p ¼ 0.016) and 17% (HR: 0.83;
95% CI: 0.73-0.95; p ¼ 0.005) relative risk reduction in
the lower 2 quartiles of EF, respectively, compared
with no difference in the upper 2 quartiles. Analysis









(n ¼ 1,750) p Value
Medications and cardiac devices
ACEi, ARB, or ARNi 1,900 (85) 1,933 (88) 1,787 (88) 1,539 (88) <0.001
ARNi 534 (24) 468 (21) 351 (17) 248 (14) <0.001
BB 2,086 (93) 2,101 (95) 1,922 (95) 1,655 (95) 0.022
MRA 1,715 (76) 1,792 (81) 1,585 (78) 1,305 (75) 0.10
(ACEi, ARB, or ARNi) þ MRA þ BB 1,413 (63) 1,511 (68) 1,387 (68) 1,114 (64) 0.37
Digitalis glycosides 450 (20) 380 (17) 304 (15) 251 (14) <0.001
SGLT2 inhibitors 64 (3) 67 (3) 44 (2) 43 (3) 0.19
Ivabradine 172 (8) 165 (8) 106 (5) 90 (5) <0.001
Cardiac resynchronization therapy 454 (20) 321 (15) 231 (11) 152 (9) <0.001
Implantable cardioverter-defibrillator 972 (43) 745 (34) 534 (26) 363 (21) <0.001
Values are mean  SD, n (%), or median (Q1, Q3), unless otherwise indicated. *Includes American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, or multiple self-identified
races.
ACEi ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; ARNi ¼ angiotensin receptor-neprilysin inhibitor; BB ¼ beta-blocker; CRT ¼ cardiac resynchronization
therapy; ED ¼ emergency department; eGFR ¼ estimated glomerular filtration rate; hsTnI ¼ high-sensitivity troponin I; ICD ¼ implantable cardioverter-defibrillator; KCCQ ¼ Kansas City
Cardiomyopathy Questionnaire; LVEF ¼ left ventricular ejection fraction; MAGGIC¼Meta-Analysis Global Group in Chronic HF; MRA ¼mineralocorticoid receptor antagonist; NT-proBNP¼ N-
terminal pro–B-type natriuretic peptide; NYHA ¼ New York Heart Association; SBP ¼ systolic blood pressure; SGLT2 ¼ sodium-glucose co-transporter 2.
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101progressively larger treatment effect of omecamtiv
mecarbil with decreasing EF (interaction p ¼ 0.004)
(Central Illustration A, Table 2). The difference in the
incidence of the primary composite endpointTABLE 2 Clinical Outcomes




(per 100 patient-yrs) n/N (%
Primary outcome
EF $33% 298/892 (33) 20.5 280/858 (
EF 29%–32% 375/1,015 (37) 23.8 356/1,011
EF 23%–28% 393/1,086 (36) 24.0 449/1,124
EF #22% 457/1,127 (41) 28.3 522/1,119 (
First HF event
EF $33% 236/892 (26) 16.2 208/858 (
EF 29%–32% 286/1,015 (28) 18.2 269/1,011
EF 23%–28% 304/1,086 (28) 18.5 345/1,124
EF #22% 351/1,127 (31) 21.7 414/1,119 (
First HF hospitalization
EF $33% 228/892 (26) 15.5 201/858 (
EF 29%–32% 279/1,015 (27) 17.6 251/1,011 (
EF 23%–28% 295/1,086 (27) 17.8 327/1,124 (
EF #22% 340/1,127 (30) 20.9 400/1,119
CV death
EF $33% 153/892 (17) 9.0 136/858 (
EF 29%–32% 196/1,015 (19) 10.5 162/1,011 (
EF 23%–28% 207/1,086 (19) 10.8 235/1,124
EF #22% 252/1,127 (22) 13.0 265/1,119 (
All-cause death
EF $33% 200/892 (22) 11.8 189/858 (
EF 29%–32% 260/1,015 (26) 13.9 226/1,011
EF 23%–28% 278/1,086 (26) 14.4 315/1,124 (
EF #22% 329/1,127 (29) 17.0 335/1,119 (
CI ¼ confidence interval; CV ¼ cardiovascular; EF ¼ ejection fraction; HF ¼ heart failureincreased disproportionately between the placebo
and omecamtiv mecarbil treatment groups with lower
EFs (Central Illustration B), such that absolute risk






Interaction p ¼ 0.013
33) 20.0 0.99 (0.84–1.16) 0.4
(35) 22.4 1.11 (0.96–1.28) 1.4
(40) 27.2 0.85 (0.74–0.97) 3.3
47) 35.6 0.83 (0.73–0.95) 7.4
Interaction p ¼ 0.004
24) 14.9 1.04 (0.86–1.25) 1.3
(27) 16.9 1.13 (0.96–1.33) 1.3
(31) 20.9 0.84 (0.72–0.98) 2.4
37) 28.3 0.81 (0.70–0.93) 6.6
Interaction p ¼ 0.004
23) 14.3 1.03 (0.85–1.24) 1.2
25) 15.5 1.19 (1.01–1.42) 2.1
29) 19.6 0.86 (0.74–1.01) 1.8
(36) 26.9 0.82 (0.71–0.94) 6.1
Interaction p ¼ 0.14
16) 8.4 1.06 (0.84–1.33) 0.6
16) 8.5 1.26 (1.02–1.55) 2.0
(21) 11.8 0.88 (0.73–1.07) 1.0
24) 14.1 0.96 (0.80–1.14) 1.1
Interaction p ¼ 0.38
22) 11.7 0.98 (0.80–1.20) 0.1
(22) 11.9 1.19 (0.99–1.42) 2.0
28) 15.8 0.89 (0.76–1.05) 1.4
30) 17.8 0.98 (0.84–1.14) 0.8
; HR ¼ hazard ratio.
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Teerlink, J.R. et al. J Am Coll Cardiol. 2021;78(2):97–108.
Estimates from Poisson regression models with ejection fraction expressed via restricted cubic spline (solid line) (dashed line, 95% confidence interval) demonstrated
the increasing beneficial relative treatment effect of omecamtiv with decreasing ejection fraction for the primary composite endpoint of time-to-first heart failure or
cardiovascular death event (interaction p ¼ 0.004 by ejection fraction as continuous variable) (A). Incidence rates (B) (events/100 patient-years) of primary composite
endpoint increased with decreasing ejection fraction in both the placebo (blue lines) and omecamtiv mecarbil group (purple lines). Omecamtiv mecarbil progressively
increases the absolute rate reduction in the primary composite endpoint with decreasing ejection fraction (C).
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102increased with decreasing EF (Central Illustration C).
In the lowest EF quartile, omecamtiv mecarbil resul-
ted in an absolute reduction of 7.4 events per 100
patient-years, with a number-needed-to-treat of 11.8
patients over 3 years necessary to prevent an event
(Table 2), compared with no reduction in the highest
EF quartile.
The beneficial effect of treatment with omecamtiv
mecarbil on the primary outcome was driven pre-
dominantly by the significant reduction in heart fail-
ure events, and EF was a significant modifier of thistreatment effect (interaction p ¼ 0.004 by EF quartile,
interaction p ¼ 0.001 by EF as continuous variable)
(Table 2). Ejection fraction had a similar modifying
effect on the progressive reduction of heart failure
hospitalizations by omecamtiv mecarbil (interaction
p ¼ 0.004 by EF quartile, interaction p ¼ 0.001 by EF
as continuous variable) (Figure 1A, Table 2). Consis-
tent with the primary composite endpoint, the inci-
dence rate of heart failure hospitalizations increases
with decreasing EF in both the placebo and ome-
camtiv mecarbil–treated patients (Figure 1B), but was
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Estimates from Poisson regression models with ejection fraction expressed via restricted cubic spline (interaction p ¼ 0.001 by ejection fraction as continuous variable)
(solid line) (dashed line, 95% confidence interval) demonstrated the increasing beneficial relative treatment effect of omecamtiv with decreasing ejection fraction for
the time-to-first heart failure hospitalization (A). Incidence rates (B) (events/100 patient-years) of heart failure hospitalizations increased with decreasing ejection
fraction in both the placebo (blue lines) and omecamtiv mecarbil group (purple lines).
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103significantly affected by treatment with omecamtiv
mecarbil, and showed a progressively greater reduc-
tion in the absolute difference with decreasing EF. EF
significantly modified the treatment of effect of
omecamtiv mecarbil on total heart failure events and
hospitalizations as well (interaction p ¼ 0.006 and p ¼
0.009, respectively) (Supplemental Table 4). Ome-
camtiv mecarbil had no overall effect on cardiovas-
cular death, either in the overall population or as a
function of baseline EF (interaction p ¼ 0.14 by EF
quartile) (Figure 2A, Table 2). As expected, the inci-
dence of cardiovascular death increased comparably
in both the placebo and omecamtiv mecarbil arms
with decreasing EF (Figure 2B, Table 2). Similarly,
there was no effect of omecamtiv mecarbil on all-
cause mortality (Table 2). The proportional hazards
assumption was evaluated for all HRs presented in
Table 2 via a test of Schoenfeld residuals. No signifi-
cant violations were detected (all p > 0.20).
OTHER OUTCOMES AND SAFETY OF OMECAMTIV
MECARBIL BY EF. Despite the reduction in heart
failure events with omecamtiv mecarbil, there was no
consistent beneficial effect on symptoms as a func-
tion of EF as assessed by the KCCQ-TSS in either the
subjects enrolled from the inpatient or outpatient
settings. However, there was a greater reduction in
NT-proBNP by omecamtiv mecarbil in patients with
lower EF such that the lowest EF quartile had a 22%
reduction (p < 0.001), whereas the highest EF quartileshowed only a 3% change (p ¼ 0.54; interaction
p < 0.001) (Table 3). Omecamtiv mecarbil treatment
resulted in a small reduction in heart rate (treatment
difference of 1.1 to 1.9 beats/min across the EF quar-
tiles) and increase in troponin I (median 3 to 5 ng/l
across the EF quartiles; limit of detection, 6 ng/l;
upper reference limit 40 ng/l), which did not differ by
EF quartile. There was no significant effect on systolic
blood pressure, serum potassium, or creatine across
the EF quartiles compared with placebo. There were
also no significant differences noted in the incidence
of adverse events between the omecamtiv mecarbil
and placebo-treated groups, except for an apparent
reduction in the incidence of adjudicated stroke for
patients treated with omecamtiv mecarbil (Table 4).
DISCUSSION
In the GALACTIC-HF trial, selectively increasing sys-
tolic function in patients with HFrEF improved car-
diovascular outcomes (primary composite endpoint
HR: 0.92; p ¼ 0.025), predominantly through reducing
heart failure events (8). Given the unique mechanism
of action of omecamtiv mecarbil, we investigated the
influence of EF on the observed treatment effects.
Omecamtiv mecarbil provided progressively greater
benefit by reducing heart failure events in patients
with lower baseline EF such that patients with an EF
below the median (#28%) had an 16% reduction in the
primary endpoint. We also observed greater
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Estimates from Poisson regression models with ejection fraction expressed via restricted cubic spline (solid line) (dashed line, 95% confidence interval) showed no
relative treatment effect of omecamtiv with decreasing ejection fraction for the time-to-cardiovascular death (interaction p ¼ 0.25 by ejection fraction as continuous
variable) (A). Incidence rates (B) (events/100 patient-years) of cardiovascular death increased with decreasing ejection fraction in both the placebo (blue lines) and
omecamtiv mecarbil group (purple lines).
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104reductions in NT-proBNP with decreasing EF, with a
22% reduction of NT-proBNP at week 24 in the lowest
EF quartile (#22%). Patients with EF in the lowest
quartile had a relative risk reduction of 17% and an
absolute risk reduction of 7.4 events per 100 patient-
years (number-needed-to-treat for 3 years ¼ 11.8) for
the primary composite endpoint.
IMPROVING CARDIAC FUNCTION WITH THE MYOTROPE
OMECAMTIV MECARBIL. Although multiple drugs have
been developed to improve inotropy (11), omecamtiv
mecarbil is the first drug to specifically increase sys-
tolic function by targeting the sarcomere without any
direct vascular, electrophysiological, or neurohor-
monal effects and without increasing mortality. It
exerts this effect by selectively binding to myosin,
stabilizing its lever arm in a primed position resulting
in an accumulation of cardiac myosin heads in the
pre-powerstroke state prior to onset of cardiac
contraction (4). This mechanism increases the num-
ber of force generators (myosin heads) that can bind
to the actin filament and undergo a powerstroke once
the cardiac cycle starts without altering the car-
diomyocyte calcium transient. Intravenous ome-
camtiv mecarbil improved cardiac performance in
early clinical studies (12–14), and as noted in the
previous text, oral omecamtiv mecarbil increased
systolic function in patients with chronic HFrEF in
the COSMIC-HF trial (5,6). The GALACTIC-HF trialprovided the first opportunity to evaluate the effect
of improving cardiac function on outcomes in pa-
tients with HFrEF. Given its mechanism of action,
there is biological plausibility to the hypothesis that
patients with greater systolic dysfunction would
derive greater benefit. In the pre-specified subgroup
analyses, EF was the most significant variable to
modify the treatment effect of omecamtiv mecarbil.
INFLUENCE OF EF ON TREATMENT EFFECTS OF
OTHER DRUGS. Reviewing data from other contem-
porary drug trials in patients with HFrEF, the rela-
tionship between treatment effect and baseline EF
has been variable. In the 11,186 patients with heart
failure and an EF #34% in sinus rhythm evaluated in
a patient-level meta-analysis of beta-blocker trials
(15), beta-blocker therapy resulted in greater relative
risk reductions in cardiovascular hospitalizations as
well as the combined endpoint of cardiovascular
hospitalizations and cardiovascular death with
decreasing baseline EF. This pattern was not as
evident for cardiovascular or all-cause mortality, and
interestingly, there was no beneficial effect of beta-
blocker therapy noted in the patients in atrial fibril-
lation. In analyses incorporating data from the
PARADIGM-HF (Prospective Comparison of ARNI with
ACEI to Determine Impact on Global Mortality and
Morbidity in Heart Failure) and PARAGON-HF (Pro-
spective comparison of Angiotensin Receptor–
TABLE 3 Omecamtiv Mecarbil Treatment Effects from Baseline to Week 24 of Selected Vital Signs and Laboratory Values
EF #22% (n ¼ 2,246) EF 23%–28% (n ¼ 2,210) EF 29%–32% (n ¼ 2,026) EF $33% (n ¼ 1,750) p Value
KCCQ total symptom score þ1.6 (0.2 to þ3.3) 0.6 (2.3 to þ1.2) þ0.3 (1.4 to þ2.0) 1.0 (2.8 to þ0.9) 0.10
Inpatient þ4.9 (þ0.8 to þ8.9) þ0.2 (3.7 to þ4.1) þ4.8 (þ0.6 to þ8.9) 0.0 (3.9 to þ3.9) 0.33
Outpatient þ0.7 (1.2 to þ2.6) 0.6 (2.5 to þ1.2) 0.8 (2.6 to þ1.1) 1.5 (3.5 to þ0.5) 0.12
Systolic BP, mm Hg 0.9 (0.4 to 2.2) 0.6 (1.9 to 0.8) 0.6 (1.9 to 0.7) 1.2 (2.7 to 0.2) 0.038
Heart rate, beats/min 1.6 (2.5 to 0.6) 1.7 (2.7 to 0.8) 1.9 (2.9 to 0.9) 1.1 (2.1 to 0.1) 0.62
Potassium, mmol/l 0.01 (0.04 to 0.05) 0.01 (0.06 to 0.03) 0.01 (0.06 to 0.03) 0.02 (0.03 to 0.06) 0.87
Creatinine, mg/dl 0.01 (0.04 to 0.02) 0.01 (0.02 to 0.04) 0.01 (0.02 to 0.04) 0.02 (0.01 to 0.05) 0.22
NT-proBNP ratio 0.78 (0.71 to 0.85) 0.90 (0.83 to 0.98) 0.95 (0.87 to 1.04) 0.97 (0.89 to 1.06) <0.001
Troponin I ratio 1.19 (1.11 to 1.27) 1.29 (1.21 to 1.38) 1.27 (1.18 to 1.36) 1.27 (1.18 to 1.37) 0.22
Troponin I, ng/l 5 (4 to 6) 4 (3 to 5) 4 (3 to 5) 3 (2 to 4) 0.055
Values represent treatment effects as evaluated by between-group differences of change from baseline to week 24 (95% confidence interval). Troponin I assay had limit of
detection of 6 ng/l with an upper reference limit of 40 ng/l.
Abbreviations as in Table 1.
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105neprilysin inhibitor with Angiotensin receptor
blocker Global Outcomes iN HF with Preserved Ejec-
tion Fraction) trials (16,17), there was no effect
modification by EF on the treatment effect of sacu-
bitril/valsartan for heart failure events or cardiovas-
cular death in patients with EF #42.5%, with a trend
toward less treatment benefit on total heart failure
hospitalizations and cardiovascular death with
decreasing baseline EF in these patients. Similarly, in
the DAPA-HF (Dapagliflozin and Prevention of
Adverse Outcomes in Heart Failure) trial, the treat-
ment effect of dapagliflozin on the primary outcome
and heart failure events in patients with an EF #35%
mildly increased with decreasing EF, and then also
had a decreasing treatment effect in patients with EF
of approximately #18% (18). In the VICTORIA (Ver-
iciguat Global Study in Subjects with Heart Failure
with Reduced Ejection Fraction) trial, which evalu-
ated the effect of vericiguat on patients with HFrEF
and EF #45%, there was a decreased hazard ratio for
the primary endpoint of time-to-first heart failure
hospitalization or cardiovascular death in the lower 2
EF quartiles (EF 24% to 29% and EF #23%) (19).
DIFFERENCES IN BASELINE CHARACTERISTICS BY
EF SUBGROUPS. Different baseline characteristics,
defined by EF subgroup, have been noted in multiple
prior heart failure studies, including the CHARM
(Candesartan in Heart failure: Assessment of Reduc-
tion in Mortality and morbidity) trials (20), the beta-
blocker trials (15), PARADIGM-HF (16) and DAPA-HF
(18). In GALACTIC-HF, patients with lower EFs were
more likely to be younger, to be men, and to have a
nonischemic etiology of heart failure, whereas they
were less likely to have atrial fibrillation, hyperten-
sion, or diabetes mellitus. Patients with lower EF also
had indicators of more severe heart failure, such asworse NYHA functional class and MAGGIC (Meta-
Analysis Global Group in Chronic HF) score, more
recent pre-randomization heart failure event, greater
NT-proBNP concentrations, as well as higher heart
rates and lower systolic blood pressure. These char-
acteristics typically interfere with initiation and up-
titration of guideline-directed medical therapy, and
as was observed in other trials, there was also an
increasing risk of heart failure hospitalizations and
cardiovascular death with decreasing EF in
GALACTIC-HF. Thus, these severely affected patients
with increasing risk are often least likely to receive or
tolerate heart failure therapies.
CLINICAL IMPLICATIONS OF THE MODIFYING EFFECT OF
EF IN GALACTIC-HF. In GALACTIC-HF, omecamtiv
mecarbil reduced the risk of heart failure events in
patients with EFs no >35%. The current analysis
demonstrates that this treatment effect increases
with decreasing EF and suggests that patients with
EFs approximately #30% are most likely to benefit
from this therapy. Additional analyses will need to be
performed to identify the patients with EFs >30%
who may also derive benefit. Although omecamtiv
mecarbil did not reduce cardiovascular death,
consistent with the overall findings in GALACTIC-HF,
omecamtiv mecarbil had no adverse effect on blood
pressure, heart rate, potassium homeostasis, or renal
function when assessed by EF quartile. The small
reduction in heart rate, believed to be due to the
secondary effect of sympathetic withdrawal, was
consistent across the EF groups. As noted in prior
trials, a minor increase in troponin I was noted across
EF subgroups with no modifying effect by EF; how-
ever, there was no evidence of adverse clinical con-
sequences (5,14). There was no difference in the
relative risk of treatment for emergent adverse
TABLE 4 Other Outcomes and Adverse Events of Special Interest
Safety Outcomes EF #22% (n ¼ 2,246) EF 23%–28% (n ¼ 2,210) EF 29%–32% (n ¼ 2,026) EF $33% (n ¼ 1,750)
Any treatment emergent
serious adverse events
Omecamtiv mecarbil 683 (60.7) 616 (56.9) 579 (57.3) 495 (55.5)
Placebo 719 (64.6) 666 (59.3) 585 (58.0) 465 (54.3)
Relative risk (95% CI) 0.94 (0.88–1.00) 0.96 (0.89–1.03) 0.99 (0.92–1.07) 1.02 (0.94–1.11)
Adverse event:
ventricular tachyarrhythmia
Omecamtiv mecarbil 97 (9.8) 80 (8.3) 62 (6.9) 51 (6.4)
Placebo 99 (9.8) 85 (8.5) 65 (7.2) 55 (7.3)




Omecamtiv mecarbil 41 (3.6) 35 (3.2) 21 (2.1) 22 (2.5)
Placebo 46 (4.1) 35 (3.1) 27 (2.7) 19 (2.2)
Relative risk (95% CI) 0.88 (0.58–1.33) 1.04 (0.65–1.65) 0.78 (0.44–1.37) 1.11 (0.61–2.04)
Adjudicated first major cardiac
ischemic events
Omecamtiv mecarbil 54 (4.8) 47 (4.3) 41 (4.1) 58 (6.5)
Placebo 45 (4.0) 49 (4.4) 38 (3.8) 56 (6.5)
Relative risk (95% CI) 1.19 (0.81–1.75) 1.00 (0.67–1.47) 1.08 (0.70–1.66) 0.99 (0.70–1.42)
Positively adjudicated
myocardial infarction
Omecamtiv mecarbil 37 (3.3) 29 (2.7) 22 (2.2) 34 (3.8)
Placebo 30 (2.7) 34 (3.0) 22 (2.2) 32 (3.7)
Relative risk (95% CI) 1.22 (0.76–1.96) 0.89 (0.54–1.44) 1.00 (0.56–1.79) 1.02 (0.64–1.64)
Adjudicated first stroke
Omecamtiv mecarbil 17 (1.5) 19 (1.8) 24 (2.4) 16 (1.8)
Placebo 26 (2.3) 37 (3.3) 29 (2.9) 20 (2.3)
Relative risk (95% CI) 0.65 (0.35–1.18) 0.53 (0.31–0.92) 0.83 (0.48–1.41) 0.77 (0.40–1.47)
Values are n (%) unless otherwise indicated.
Abbreviations as in Tables 1 and 2.
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compared with placebo. Thus, therapy with ome-
camtiv mecarbil could be initiated in appropriate
patients at any time in their clinical course without
interfering with the initiation or up-titration of life-
saving guideline directed medical therapy.
STUDY LIMITATIONS. Although the analysis of
GALACTIC-HF by EF was pre-specified, subgroup
analyses have inherent limitations. Many subgroup
analyses have limited sample sizes and number of
events. The evaluation of EF by quartiles in the cur-
rent analysis has subgroups of approximately 2,000
patients with 578 to 979 events in each quartile,
subgroups in themselves larger than many studies.
These investigations are supported by analyses of EF
as a continuous variable incorporating the data from
all 8,232 patients. Although the statistical analysis
plan from GALACTIC-HF pre-specified multiple sub-
groups for evaluation and is subject to issues relatedto multiplicity testing, the univariate interaction p
value for the treatment-covariate interaction was
0.004 and was 0.009 after adjustment for all other
pre-specified subgroups, making it highly unlikely to
be due to chance. In addition, there is biological
plausibility for this effect modification, and the
findings are internally consistent. Other potential
limitations are that the EF was the investigator-
reported, the most recent value within 12 months
prior to randomization, and it was not measured by a
core laboratory or immediately prior to randomiza-
tion. Although this approach is more consistent with
clinical practice, where EFs are measured in response
to specific clinical events, there is the possibility that
the reported EF is not reflective of the baseline EF at
the time of enrollment. To mitigate this possibility,
investigators were instructed to repeat the measure-
ment if there had been an intervening event that
might have changed its value. This analysis only as-
sesses the influence of 1 variable, the baseline EF, on
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107the treatment effect of omecamtiv mecarbil. Clearly,
other baseline characteristics can influence the
response to a therapy in patients with HFrEF. As
noted in the previous text, in the large analysis of
patients with heart failure treated with beta-blockers,
patients with atrial fibrillation at baseline had mini-
mal to no beneficial clinical effect regardless of
baseline EF (15). Similarly, other comorbidities or
markers of disease severity may modify the treatment
effect of omecamtiv mecarbil.
CONCLUSIONS
In GALACTIC-HF, treatment with omecamtiv mecarbil
was associated with greater reductions in heart failure
events in patients with lower baseline EF. Combined
with the high risk of heart failure events in these pa-
tients, patients treated with omecamtiv mecarbil dis-
played an even greater relative treatment effect and a
progressively larger absolute risk reduction for the
primary composite endpoint of heart failure events
and cardiovascular death with lower baseline EF.
These findings support the concept that patients with
more severe heart failure derive greater clinical
benefit from cardiac myosin activator therapy.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCE-
DURAL OUTCOMES: In patients with left ventricular
EF #35% receiving guideline-directed therapy, those
with more severe ventricular systolic dysfunction exhibit
the greatest reductions in heart failure hospitalization or
cardiovascular death during treatment with the cardiac
myosin activator omecamtiv mecarbil.
TRANSLATIONAL OUTLOOK: Further analyses could
identify patient characteristics other than EF that are
associated with greater clinical responsiveness to ome-
camtiv mecarbil and define its place in the optimum
sequence of pharmacological interventions for patients
with HFrEF of various etiologies.
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